Novartis GC resignation points to compliance themes
The resignation of Novartis GeneraI Counsel Felix Ehrat shows companies the importance of distinguishing between the legal and compliance functions and why you should always get a business justification before working with third parties.
Related articles
-
ArticleNovartis’ latest settlements: $729M in kickback charges
A week after resolving FCPA investigations for $347 million, Swiss pharmaceutical drug maker Novartis will pay another $729 million in separate settlements related to kickback schemes.
-
ArticleNovartis to pay $347M to resolve FCPA investigations
Novartis will pay nearly $347 million in combined criminal and civil penalty settlements with U.S. authorities to resolve all FCPA investigations into historical conduct by the company and its subsidiaries.
-
WebcastCPE Webcast: How to Build Holistic Risk and Resilience Management
Risk, compliance, and business continuity teams often run in parallel, but what if they worked better together? As risks become more interconnected and the pressure to respond quickly grows, companies are realizing that a siloed approach doesn’t cut it anymore.